Australia’s Therapeutic Goods Association (TGA) has approved the use of the protein-based immune-boosting vaccine Arexvy to combat the respiratory syncytial virus (RSV).
Jim Birchall
Author
Jim Birchall has written and edited for several regional New Zealand publications. He was most recently the editor of the Hauraki Coromandel Post.
